Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an honorarium for his participation and contribution to this webinar.

Swiss start-up Granite Bio has carved out $100 million in a pair of financings for its pipeline of potentially first-in-class antibodies for autoimmune diseases. The Basel-based company has one ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.

President Donald Trump has signed an executive order aimed at lowering drug prices for Americans that includes a plan to do away with what the industry claims is a major flaw in the Biden era ...

Accurate, timely, and connected data on key opinion leaders (KOLs) - encompassing their scientific and digital activities, collaborations, and associations - has become critical for success at ...

The White House has launched a national security investigation into the national security implications of importing pharmaceuticals, viewed as a precursor step on the way to tariffs threatened by ...

Pharmaceutical companies approach a significant wave of patent expirations by 2030. This includes exclusivity rights set to expire for 569 medications valued at $278 billion, based on 2022 sales.

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of disease. However, cell and gene therapy (CGT) is ...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...